Processing...
Clinical Trials for Ovarian Cancer
Search
Search
There are 212 active trials for advanced/metastatic ovarian cancer.
Click on a trial to see more information.
212 trials meet filter criteria.
Sort by:
HealthScout AI summary: Adults with advanced or metastatic solid tumors harboring specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) are eligible for treatment with LY4066434, a highly selective small molecule pan-KRAS inhibitor, given as monotherapy or in combination with standard chemotherapy or immunotherapy regimens. Active CNS metastases and significant unresolved toxicities are exclusion criteria.
ClinicalTrials.gov ID: NCT06607185
HealthScout AI summary: Adults with unresectable, advanced, or metastatic solid tumors (including NSCLC, colorectal, HNSCC, pancreatic, ovarian, or breast cancer) that are both HLA-A*02:01 positive and harbor the TP53 R175H mutation, and who have progressed on prior therapy, may receive NT-175, an autologous T cell product genetically engineered with a TCR targeting TP53 R175H and rendered resistant to TGF-β mediated immunosuppression. Treatment includes leukapheresis, lymphodepletion (fludarabine/cyclophosphamide), NT-175 infusion, and short-course subcutaneous IL-2.
ClinicalTrials.gov ID: NCT05877599
HealthScout AI summary: This trial enrolls adults with unresectable or metastatic solid tumors expressing MAGE-A1, MAGE-A4, MAGE-C2, PRAME, or HPV16 antigens and specified HLA types, who have exhausted standard treatments. Participants receive autologous TCR-engineered T cells (TCR-T) targeting these antigens, as monotherapy or in combination, following lymphodepleting chemotherapy.
ClinicalTrials.gov ID: NCT05973487
HealthScout AI summary: Adults with advanced solid tumors—such as high grade serous ovarian, squamous NSCLC, triple negative breast, gastric, colorectal, esophageal, bladder, head and neck, and select gynecologic cancers—who have progressed on standard therapies receive oral VLS-1488, a selective inhibitor of the mitotic kinesin KIF18A, given in 28-day cycles. Patients with active CNS metastases, prior KIF18A inhibitor exposure, or MSI-H/dMMR tumors are excluded.
ClinicalTrials.gov ID: NCT05902988
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors expressing Nectin-4 who have progressed after or are ineligible for standard systemic therapy, excluding those with brain metastases or serious comorbidities. Patients receive IPH4502, a novel antibody-drug conjugate targeting Nectin-4 with an exatecan payload, administered as monotherapy.
ClinicalTrials.gov ID: NCT06781983
HealthScout AI summary: Eligible patients are adults with advanced, refractory solid tumors (including soft-tissue sarcoma, triple-negative breast cancer, NSCLC, cervical cancer, ovarian cancer, or KRAS-mutant pancreatic ductal adenocarcinoma), who have not previously received anthracyclines. The trial investigates Spedox-6, a novel human serum albumin-encapsulated doxorubicin formulation designed to enhance tumor delivery and reduce cardiotoxicity, given IV every 21 days at escalating doses (with filgrastim support at higher doses).
ClinicalTrials.gov ID: NCT07064018
HealthScout AI summary: This trial enrolls adults with advanced solid tumors—including HNSCC, NSCLC, GI, GU, gynecologic, sarcoma, neuroendocrine, and NUT carcinoma—who have measurable disease and good performance status, to evaluate the intravenous BRD4 degrader MT-4561 administered weekly. MT-4561 is a novel agent targeting BRD4 for ubiquitin-mediated degradation and is being assessed primarily for safety and initial efficacy in this biomarker-unselected population.
ClinicalTrials.gov ID: NCT06943521
HealthScout AI summary: Enrolling adults with locally advanced or metastatic epithelial cancers (including multiple breast cancer subtypes, NSCLC, cervical, prostate, pancreatic, head and neck, endometrial, ovarian, gastric/GEJ, or urothelial carcinomas) who have progressed after ≥2 prior therapies and lack standard options, this study delivers IV DR-0202, a bispecific antibody targeting CLEC7A on myeloid cells and a tumor-associated antigen, aiming to activate myeloid-driven phagocytosis and antitumor immunity.
ClinicalTrials.gov ID: NCT06999187
HealthScout AI summary: This trial enrolls adults with unresectable, locally advanced, or metastatic HER2-positive or HER2-mutant solid tumors (including but not limited to breast, gastric/GEJ, NSCLC, endometrial, ovarian, and urothelial cancers) who have progressed on or are not candidates for standard therapy. Patients receive BL-M17D1, an investigational HER2-targeted antibody-drug conjugate, given intravenously on Days 1 and 8 of a 21-day cycle.
ClinicalTrials.gov ID: NCT06714617